Kroger Specialty Pharmacy is Now Dispensing, Providing Enhanced Support, and Bridge Access for Eligible Patients for BIMZELX®
UCB has selected Kroger Specialty Pharmacy as one of the Network Specialty Pharmacies to dispense BIMZELX® for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Kroger Specialty Pharmacy is now dispensing BIMZELX® (bimekizumab-bkzx), a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet light alone or with pills (phototherapy). BIMZELX® (injection for subcutaneous use) is the first and only IL-17A and IL-17F inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis.
At Kroger Specialty Pharmacy, our highly qualified clinical and patient care teams are specially trained in dermatology care. Their unique skills and experience allow them to help navigate the complexities that arise from complex medication therapies. Our Clinical Pharmacist Liaison Program establishes a higher level of clinical support through our seasoned autoimmune pharmacists that streamline the referral process, provide enhanced treatment support, and clarify medication guidelines.
Jeremy Richardson, Vice President of Sales, Marketing and Trade Relations for Kroger Specialty Pharmacy, shared the importance of expanding our LDD offering to include BIMZELX® for patients with plaque psoriasis. “UCB is an expert in biologic products and our KSP clinical team is equally equipped to provide exceptional service for this new therapy offering. As a trusted partner with over twenty years of experience in the dermatology space, KSP removes barriers to care and enhanced service for patients to provide a high touch caring experience throughout their healthcare journey. We understand the importance of this product and are excited to participate as a bridge dispensing pharmacy to fast track time to therapy and increase patient quality of life. KSP is thrilled to partner with UCB in this launch to deliver a superior experience to patients on BIMZELX®.”
At Kroger Specialty Pharmacy our clinical and care teams have extensive experience with the treatment challenges that can arise when dealing with complex chronic diagnoses. We are passionate about simplifying the enrollment process for our patients by providing comprehensive financial services and personalized patient care support.
For more information about BIMZELX®, please contact our dedicated Autoimmune team at 888.355.4191.
About Kroger Specialty Pharmacy:
At Kroger Specialty Pharmacy, our mission is to be the preferred pharmacy for people undergoing complex medication therapies by optimizing clinical outcomes and providing a high-touch, caring experience. As the largest independent specialty pharmacy by provider choice, Kroger Specialty Pharmacy offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Oncology – as well as Dermatology, HIV, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, HAE plus others. Kroger Specialty Pharmacy services patients in all 50 states and Puerto Rico and is ACHC and URAC Accredited in numerous sites. Kroger Specialty Pharmacy's clinically effective and cost-efficient therapy management programs provide direct value to healthcare organizations nationwide. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. For more information, visit www.krogerspecialtypharmacy.com.
About UCB:
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,700 people in approximately 40 countries, the company generated revenue of €5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.
BIMZELX® and UCBCares® are registered trademarks, and BIMZELX Navigate™ is a trademark, of the UCB Group of Companies. All other trademarks and registered trademarks are the property of their respective holders. ©2023 UCB, Inc., Smyrna, GA 30080. All rights reserved.